UK's MHRA approves single-dose 7.2mg Wegovy pen for adults with obesity
UK prescribers can issue the full 7.2mg Wegovy dose as a single weekly injection
Change
The UK Medicines and Healthcare products Regulatory Agency (MHRA) approved a single‑dose 7.2mg semaglutide (Wegovy) pen for adults with obesity with Body Mass Index (BMI) of 30 kg/m² or higher, allowing the maximum weekly dose to be delivered in one injection rather than three 2.4mg injections.
Why it matters
Prescribers must follow the approved dosing pathway, starting at 0.25mg and escalating every four weeks to reach the 7.2mg maximum. The single‑dose pen is authorised only for adults with a BMI of 30 kg/m² or higher and not for patients under that threshold or for use solely to reduce cardiovascular risk.
Implications
- — UK prescribers of obesity and weight‑management treatments — must confirm patient BMI is 30 kg/m² or higher before prescribing the single‑dose 7.2mg Wegovy pen — prescribing to ineligible patients will be off‑label and risk professional or regulatory scrutiny immediately.
- — UK hospital and community pharmacists — must update dispensing checks and labelling workflows now to distinguish 7.2mg single‑dose pens from existing 2.4mg pens — failure to do so risks dispensing errors and patient safety incidents requiring Yellow Card reporting.
Unlock the decision layer.
- Implications: What this forces you to change — operations, exposure, or compliance.
- Who is affected: Which roles, contracts, and obligations are exposed.
- What to watch: Binding deadlines and enforcement dates.
- Real-time alerts: Delivered the moment a binding change is published.
- Ask AI: Ask what this means for your specific role.
No credit card · 14-day trial · Active in seconds
Unlock the decision layer
Source
gov.uk
View on gov.uk